PLK4 and cancer: Inhibition of PLK4 activity by various compounds such as centrinone, centrinone B, CFI-400945, YLZ-F5, and RP-1664 has been shown to confer antitumorigenic effects and sensitize cancer cells to various chemotherapeutic drugs, targeted therapies and radiation (Table 2).